Li Tao, Yao Weina
Emergency Center, Jinan Zhangqiu District Hospital of TCM, Jinan, Shandong 250200, P.R. China.
Department of Cardiovascular Medicine, The First People's Hospital of Jinan, Jinan, Shandong 250000, P.R. China.
Exp Ther Med. 2018 Nov;16(5):4119-4123. doi: 10.3892/etm.2018.6669. Epub 2018 Aug 30.
This study aimed to investigate the therapeutic effect of irbesartan combined with atorvastatin calcium in the treatment of rats with coronary heart disease. One hundred sixty Wistar rats were selected to establish coronary heart disease model. Rats with coronary heart disease were randomly divided into 4 groups: Model, irbesartan, atorvastatin calcium and combination groups (irbesartan combined with atorvastatin calcium group). Rats in irbesartan group were treated with 50 mg/(kg.day) irbesartan; rats in atorvastatin calcium group were given atorvastatin calcium at a dose of 10 mg/(kg.day); rats in combination group were subjected to atorvastatin calcium at a dose of 10 mg/(kg.day) and irbesartan at a dose of 50 mg/(kg.day), while rats in model groups were given intragastric administration of normal saline at a dose of 2 ml/day. Serum lipids, including total cholesterol (TC), triglyceride (TG), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C) and TC/HDL-C, were measured by automatic biochemical analyzer. Expression of sPLA2-V in myocardium and aortic trunk of rats was detected by reverse transcription-PCR (RT-PCR) and western blot analysis. After treatment, levels of serum TC, TG, LDL-C, HDL-C and TC/HDL-C in rats of each treatment group were better than those in model group (p<0.05). Expression level of sPLA2-V in myocardium and aortic trunk in model group was significantly higher than that in other groups (p<0.05). Expression level of sPLA2-V in combination group was significantly lower than that in irbesartan and atorvastatin calcium groups (p<0.05). Combination of irbesartan and atorvastatin calcium is superior to irbesartan or atorvastatin calcium alone in the treatment of rats with coronary heart disease. The possible explanation is that the two drugs can reduce the expression of sPLA2-V in myocardium and aortic trunk, which in turn relieved atherosclerosis and achieved better therapeutic effect.
本研究旨在探讨厄贝沙坦联合阿托伐他汀钙治疗冠心病大鼠的疗效。选取160只Wistar大鼠建立冠心病模型。将冠心病大鼠随机分为4组：模型组、厄贝沙坦组、阿托伐他汀钙组和联合组（厄贝沙坦联合阿托伐他汀钙组）。厄贝沙坦组大鼠给予50 mg/(kg·天)厄贝沙坦；阿托伐他汀钙组大鼠给予10 mg/(kg·天)阿托伐他汀钙；联合组大鼠给予10 mg/(kg·天)阿托伐他汀钙和50 mg/(kg·天)厄贝沙坦，而模型组大鼠给予2 ml/天的生理盐水灌胃。采用自动生化分析仪检测血清脂质，包括总胆固醇(TC)、甘油三酯(TG)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)和TC/HDL-C。通过逆转录聚合酶链反应(RT-PCR)和蛋白质免疫印迹分析检测大鼠心肌和主动脉干中sPLA2-V的表达。治疗后，各治疗组大鼠血清TC、TG、LDL-C、HDL-C和TC/HDL-C水平均优于模型组(p<0.05)。模型组心肌和主动脉干中sPLA2-V的表达水平显著高于其他组(p<0.05)。联合组中sPLA2-V的表达水平显著低于厄贝沙坦组和阿托伐他汀钙组(p<0.05)。厄贝沙坦与阿托伐他汀钙联合治疗冠心病大鼠优于单用厄贝沙坦或阿托伐他汀钙。可能的解释是，这两种药物可以降低心肌和主动脉干中sPLA2-V的表达，从而减轻动脉粥样硬化，取得更好的治疗效果。
